Riitta Lassila on LMWH Benefits in COVID19
Riitta Lassila, Professor of Coagulation Medicine at University of Helsinki, shared on LinkedIn:
”We are happy to report RDW benefits from early high risk (the same for corona disease progression and thrombosis) – targeted LMWH prophylaxis initiated at outpatient setting.
The two first virus waves when vaccination program had only started.
Lessons for any future severe viral outbursts.”
Read the full article here.
Article: Early outpatient use of low-molecular-weight heparin benefits COVID-19 outcome in association with hospitalization – Lessons learned
Authors: Miika Koskinen, Eeva Ruotsalainen, Mia Wallin, Hilkka Kivelä, Kerstin Carlsson, Jari Petäjä, Eero Hirvensalo, Markku Mäkijärvi, Riitta Lassila
Stay updated on all scientific advances with Hemostasis Today.
-
May 13, 2026, 07:35Ifeanyichukwu Ifechidere: Why DIC is the Condition That Humbles even the Most Experienced Scientists
-
May 13, 2026, 07:26Genoveva Uzunova: Why It’s Time to Close the Sex Variable Gap in Healthcare
-
May 13, 2026, 07:09Auston Cherbonneaux: Why Erythritol Just Joined the High-Hazard List
-
May 13, 2026, 06:48Akshat Jain: Transforming Sickle Cell Care With Practical Apheresis Frameworks
-
May 13, 2026, 06:35Dima Shulkin: How Neutrophil Extracellular Traps Shape ACS
-
May 13, 2026, 05:50Danny Hsu: Global Maternal VTE Awareness and Opportunities for Prevention
-
May 13, 2026, 05:50Ney Carter Borges: Clinical Cardiovascular Polygenic Risk Report for 8 Conditions
-
May 13, 2026, 05:49Kalyan Roy: A New Blood Group System Has Been Discovered
-
May 13, 2026, 05:07Azin Alizadehasl: Unraveling DIC in Cancer-Driven Coagulopathy